Ocugen Inc. (OCGN)
0.65
0.04 (6.52%)
At close: Feb 28, 2025, 3:59 PM
0.65
-0.02%
After-hours: Feb 28, 2025, 05:55 PM EST
No 1D chart data available
| Bid | 0.65 |
| Market Cap | 189.12M |
| Revenue (ttm) | 9.35M |
| Net Income (ttm) | -49.78M |
| EPS (ttm) | -0.19 |
| PE Ratio (ttm) | -3.42 |
| Forward PE | -2.67 |
| Analyst | Buy |
| Ask | 0.65 |
| Volume | 2,696,452 |
| Avg. Volume (20D) | 4,574,266 |
| Open | 0.62 |
| Previous Close | 0.61 |
| Day's Range | 0.60 - 0.66 |
| 52-Week Range | 0.60 - 2.10 |
| Beta | 3.83 |
About OCGN
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related ...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 3, 2014
Employees 65
Stock Exchange NASDAQ
Ticker Symbol OCGN
Website https://www.ocugen.com
Analyst Forecast
According to 3 analyst ratings, the average rating for OCGN stock is "Buy." The 12-month stock price forecast is $6, which is an increase of 823.08% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Ocugen Inc. is scheduled to release its earnings on Mar 5, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
7 months ago
-7.8%
Ocugen shares are trading lower after the company ...
Unlock content with
Pro Subscription
7 months ago
-4.08%
Ocugen shares are trading lower after the company announced an underwritten public offering.
